Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 19/20 | 0.73 |
| ▸ | TPSB2 | P20231 | 9/20 | 0.58 |
| ▸ | F11 | P03951 | 8/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23241512 | 1.00 | CFD (0.73) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL23240919 | 1.00 | CFD (0.73) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL29672917 | 1.00 | CFD (0.73) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL21438029 | 0.92 | CFD (0.74) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL21455501 | 0.92 | CFD (0.74) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL21437503 | 0.91 | CFD (0.79) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL21455670 | 0.91 | CFD (0.75) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL21455105 | 0.91 | CFD (0.75) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL21437705 | 0.91 | CFD (0.75) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL23616671 | 0.91 | CFD (0.78) | CFDTPSB2F11PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |